Accepted Manuscript

Endoscopy International Open

EUS-guided hydrogel injection to separate pancreatic head carcinoma from duodenum for enhanced radiotherapy: multi-site feasibility study

Manoop Bhutani, Amol Narang, Kai Ding, Brenna W Casey, Kumar Krishnan, Eugene Koay, Theodore S Hong, Joseph Herman, Kristen Griffin, Eun Ji Shin.

Affiliations below.

DOI: 10.1055/a-2286-1995

Please cite this article as: Bhutani M, Narang A, Ding K et al. EUS-guided hydrogel injection to separate pancreatic head carcinoma from duodenum for enhanced radiotherapy: multi-site feasibility study. Endoscopy International Open 2024. doi: 10.1055/a-2286-1995

Conflict of Interest: Manoop Bhutani: Nanobiotix, Trisalis, Oncosil, Starpax Medical, Augmenix/Boston Scientific

Amol Narang: Boston Scientific, Flavocure, Nanocan Therapeutics Corporation

Kai Ding: Boston Scientifc

Casey Brenna: no COI to declare

Kumar Krishnan: Boston Scientific, Olympus

Eugene Koay: RenovoRx, Quantum Aurea Capital, Kallisio, International Cholangiocarcinoma Research Network

Theodore S. Hong: Synthetic Biologics, Novocure, Boston Scientific, Inivata, Merck, GSK, PanTher Therapeutics, Lustgarten, Taiho, AstraZeneca, BMS, GSK, IntraOp, Ipsen

Joseph Herman: Histosonics, Boston Scientific, Canopy Cancer Collective

Kristen Griffin: Boston Scientific (employee)

Eun Ji Shin: Boston Scientific

This study was supported by Boston Scientific Corporation (http://dx.doi.org/10.13039/100008497)

Trial registration: NCT03998566, ClinicalTrials.gov (http://www.clinicaltrials.gov/), Multi-Center Feasibility Study

Abstract:

Background and study aims: The proximity of a pancreas head tumor to the duodenum often limits delivery of an ablative dose of radiation therapy. This study evaluated the feasibility and safety of using an injectable polyethylene glycol (PEG) hydrogel between the head of the pancreas and duodenum.

Patients and methods: In a multi-site feasibility cohort study of patients with localized pancreatic cancer, PEG hydrogel was injected under endoscopic ultrasound guidance to temporarily position the duodenum away from the pancreas. Procedure characteristics were recorded, including hydrogel volume and space created. Patients were monitored for adverse events (AEs) and radiotherapy toxicity.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Results: In all six intent-to-treat patients (four with borderline resectable, two with locally advanced disease), the ability to place and visualize PEG hydrogel and create space between the duodenum and head of pancreas was successful. There were no procedure-related AEs resulting in radiotherapy delay. There were no device-related AEs and no reports of pancreatitis. Conclusions: PEG hydrogel was successfully placed, created space between the duodenum and the head of the pancreas, and was not associated with major toxicity. Enhancing radiotherapy for pancreatic cancer by using PEG hydrogel to create peri-duodenal space could have beneficial implications for treatment and warrants more exploration.

Corresponding Author:

Dr. Manoop Bhutani, University of Texas MD Anderson Cancer Center, Gastroenterology, 1515 Holcombe Blvd., 77030-4000 Houston, United States, Manoop.Bhutani@mdanderson.org

Affiliations:

Manoop Bhutani, University of Texas MD Anderson Cancer Center, Gastroenterology, Houston, United States Amol Narang, Johns Hopkins University, Department of Radiation Oncology and Molecular Radiation Sciences, Baltimore, United States Kai Ding, Johns Hopkins University, Department of Radiation Oncology and Molecular Radiation Sciences, Baltimore, United States [...]

Eun Ji Shin, Johns Hopkins Medicine, Internal Medicine, Baltimore, United States

nce of R Jiat

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Supplementary Material

Supplementary Table 1. Duodenal AE summary by CTCAE grade and timing

	Total	One or more acute	One or more late
	(N=6)	(<=3 months)	(>3 months)
		(N=6)	(N=6)
Patients who have one or more grade 1 duodenal AEs	6 (100.0%)	6 (100.0%)	4 (66.7%)
Patients who have one or more grade 2 duodenal AEs	4 (66.7%)	3 (50.0%)	3 (50.0%)
Patients who have one or more grade 3 duodenal AEs	2 (33.3%)	0 (0.0%)	2 (33.3%)
Patients who have one or more grade 4 duodenal AEs	0 (0.0%)	0 (0.0%)	0 (0.0%)
Patients who have one or more grade 5 duodenal AEs	0 (0.0%)	0 (0.0%)	0 (0.0%)
Patients who only have grade N/A duodenal AEs	0 (0.0%)	0 (0.0%)	0 (0.0%)
Patients who have one or more duodenal AEs	6 (100.0%)	6 (100.0%)	4 (66.7%)

Supplementary Table 2. Histology of Duodenal Tissues for Resected Patients

		Resected (N=3)
		, ,
Pathological Duodenum Damage Scoreª	No/Minimal	3 (100.0%)
	Moderate Damage	0 (0.0%)
	Severe Damage	0 (0.0%)
Pathologic Response ^b	Complete	1 (33.3%)
	Near Complete (near complete and limited response)	2 (66.7%)
	No Response	0 (0.0%)

^aThe pathological duodenum damage score was rated by a local board-certified gastrointestinal surgical pathologist using the methods outlined by Verma et al. (1=No/minimal signs of mucosal damage, 2=Moderate damage, 3=Severe damage)

^bPathologic response was graded according to the College of American Pathologists (CAP) Protocol for the Examination of Specimens from Patients with Carcinoma of the Pancreas

Introduction

Pancreatic cancer has a poor prognosis, with over half of cases diagnosed at distant stage.[1] Less than 20% of patients have resectable disease.[2] Delivery of high-dose ablative radiation therapy (RT) is effective for some cancers, but for the pancreas, the amount of radiation possible is limited by surrounding anatomy and the risk for significant duodenal toxicity.[3]

The concept of creating space proximal to a primary tumor has shown promise in prostate cancer populations undergoing RT,[4, 5] prompting an interest in its application for other cancers. PEG hydrogel[6-8] addresses some limitations of previously tested biomaterials used for spacing.[9] Hydrogel can be distributed evenly for precise and durable spacing, and the water-soluble molecules reliably degrade and excrete through renal filtration months after application.[10]

There is evidence from porcine and cadaver studies of the feasibility of endoscopic ultrasound (EUS)-guided injection of PEG hydrogel into the space between the head of the pancreas (HOP) and the duodenum, increasing space for RT administration.[6, 11] A first-in-human single-site pilot study showed feasibility of administering PEG hydrogel and creating space in patients with pancreatic cancer undergoing ultra-hypofractionated stereotactic body radiotherapy (SBRT).[7] In this multi-site study of a similar population, we sought to evaluate with greater generalizability the feasibility, RT benefits, and safety of using an injectable PEG hydrogel to create space between the pancreas and duodenum. Here we report on technical and safety outcomes of PEG hydrogel administration; RT findings have been reported separately.[12]

Materials and Methods

Study Design:

This was a multi-center prospective, single-arm early feasibility study (April 24, 2019-May 1, 2021) of a PEG hydrogel used as a spacer in six patients with localized (resectable, borderline resectable or locally advanced) pancreatic cancer for whom a course of RT was indicated. The trial was registered at ClinicalTrials.gov (NCT03998566).

Patients:

Inclusion criteria were: age \geq 18 years; biopsy-confirmed localized pancreatic cancer in the head or neck of the pancreas visualized via CT or other imaging modality with no evidence of distant metastasis as defined by NCCN guidelines; tumor clearly delineable from duodenum and no clear evidence of invasion of the duodenum; RT was indicated; medically fit to undergo endoscopy; screening/baseline laboratory testing met established laboratory value criteria; and life expectancy of at least 9 months.

Patients were excluded for any of the following: RT was contraindicated; history of previous thoracic or abdominal RT; presence of tumor invasion of the duodenum detected on EUS at time of biopsy; previous Whipple procedure or other resection of pancreatic tumor prior to screening; active gastroduodenal ulcer or uncontrolled watery diarrhea; history of chronic renal failure; history of uncontrolled diabetes; enrolled in another investigational drug or device trial that would clinically interfere with this study; or unable to comply with the study requirements or follow-up schedule.

Patients provided written consent before study-specific procedures were performed. The study was approved by the Institutional Review Board of the respective clinical sites (July 3-31, 2018).

Index Procedure:

TraceIT Tissue marker ("TraceIT," Augmenix, Waltham, MA, USA) is an absorbable radiopaque PEG hydrogel material, currently FDA-cleared to radiographically mark soft tissue during a surgical procedure or for future surgical procedures for at least three months after injection. In this study, TraceIT was administered for an off-label use, soft tissue spacing in the duodenal pancreatic groove, to temporarily position the duodenum away from the pancreas in patients undergoing RT for treatment of pancreatic cancer.

Enrolled patients underwent placement of fiducial markers into the pancreatic head tumor and peri-duodenal administration of PEG hydrogel within the same EUS procedure. Patients were positioned in the left lateral position and a linear EUS was used to identify the duodenal wall, pancreas head tumor, and HOP interface. Under EUS guidance, a 22G fine needle aspiration was advanced into the potential space between the duodenum and pancreas. PEG hydrogel was prepared per the instructions for use. The single-use kit consists of a pre-filled glass syringe containing the absorbable radiopaque cross-linked PEG hydrogel spacer and a delivery system (syringe and needle) (Figure 1a). Immediately before injection, the PEG hydrogel was mixed five times between the two syringes and placed in a plastic receiving syringe. Once the needle was confirmed to be in the proper position, hydrogel was injected in 1-2mL increments. This process was repeated as the needle was repositioned around the target (Figure 1b).

After each procedure, the following was collected: ability to access injection site and inject PEG hydrogel; average duodenal space measurements on CT measured at three points along the HOP; injection procedure duration; ease of device use; device malfunctions; and adverse events (AEs) per NCI Common Terminology Criteria for Adverse Events (CTCAE v4). Any event precipitating an intestinal acute CTCAE score of 2 or higher was documented as an AE.

RT simulation planning was performed prior to and following PEG hydrogel placement for evaluation and comparison of duodenal dose/dose distribution and to assess differences in RT dosing parameters. RT was to be initiated no later than 28 days following PEG hydrogel administration.

Within two to six weeks after RT completion, patients were restaged to determine whether they could progress to surgery. If surgical resection was successful, pathological data were recorded. All patients were evaluated at minimum three and six months post-index procedure. MRI was performed at the six-month visit to evaluate for PEG hydrogel presence in unresected patients. Throughout the study, patients were assessed for duodenal AEs. Additional follow-up clinic visits were performed per standard care at 12 and 18 months at minimum.

Study Endpoints:

Effectiveness: Feasibility was defined as technical success, i.e., the ability to administer and visualize PEG hydrogel and create space between the duodenum and HOP; the technical success rate was calculated as the proportion of patients who achieved technical success in the intention-

to-treat (ITT) population. RT benefits were assessed via comparison of pre- and postadministration RT plans and have been reported separately.[12]

Safety: Patients were monitored for AEs and RT toxicity (using CTCAE v4) and in particular, for PEG hydrogel administration procedure-related events resulting in a delay in initiation of RT, as reviewed and adjudicated by a Clinical Events Committee.

Additional data collection included: incidence of resection; histology of duodenal tissues when resection was performed; incidence of acute (\leq 3 months) and late (>3 months) duodenal toxicity for unresected patients; theoretical dose escalation from post-injection treatment plan (reported separately); PEG hydrogel persistence (6-months post-treatment in unresected patients); and progression-free and overall survival through follow-up. Histology of the duodenal tissues was assessed when resection was performed. The pathological duodenum damage score was rated by a local board-certified gastrointestinal surgical pathologist using the methods outlined by Verma et al. (1=No/minimal signs of mucosal damage, 2=Moderate damage, 3=Severe damage).[13] Pathologic response was graded according to the College of American Pathologists (CAP) Protocol for pancreatic cancer.[14]

Screening/Baseline data collection:

Information collected at screening and baseline included: demographics; disease documentation (tumor location, initial resectability status, tumor staging, pre-treatment tumor dimension); medical/surgical history and status (concomitant medical conditions, prior surgeries, prior therapies); physical examination; assessment of baseline duodenal symptoms; and baseline concomitant medications

Results

Enrollment in analysis population:

A total of eight patients were consented. One was consented but did not meet the eligibility criteria and was deemed a screen failure. Another was consented but withdrew consent before eligibility criteria was verified. This left six patients in the ITT population. There were no major protocol deviations with the potential to affect the study.

Baseline characteristics:

The median and age range of the patients enrolled was 69.5 (60-80) (Table 1). The majority were male (66.7%) and 50.0% were white. All subjects received neoadjuvant therapy for pancreatic cancer. There were four patients (66.7%) who were in borderline resectable stage while two patients (33.3%) were in the locally advanced stage. RT planning and treatment characteristics will be reported separately; briefly, five of six patients were treated with SBRT and one with intensity-modulated RT.

Feasibility/Technical Success:

The ability to place and visualize PEG hydrogel, creating space between the duodenum and the HOP was successful in all patients (100%, N=6).

PEG Hydrogel Administration and Space Created:

The median time between hydrogel injection and initiation of RT was 18 days (range: 9-19

days). PEG hydrogel was distributed in small volumes (~1 to 2 mL per injection for up to a total of 10 mL) at several areas along the proximal portion of the duodenum in the areas closest to the head of the pancreas (HOP). The precise location of each injection varied according the anatomy and tumor characteristics of each case. Table 2 presents injection characteristics by patient. Figure 2 shows the space created in two patients on EUS. Figure 3 shows the hydrogel between the duodenum and pancreatic head tumor on CT scan.

Of the three unresected patients able to be assessed for persistence at two to six weeks post-RT, PEG hydrogel was still present in all. At six months post-RT, in the two patients who received imaging and were assessed for persistence, PEG hydrogel was not detected. Stability was similar from the time of placement to two to six weeks afterwards, based on the distance from a fiducial marker ($8.2 \pm 5.9 \text{ mm vs } 8.5 \pm 10.2 \text{ mm}$, N=3).

Safety/Adverse Events:

No procedure-related AEs resulting in a delay in RT initiation were reported. Two patients (33.3%) had procedure-related AEs; these took place at two sites. One of these patients was reported to have sinus bradycardia; the other had nausea, chills, dehydration, and stomach pain. All of these AEs were noted as resolved. There were no device-related AEs. There were no reports of pancreatitis, perforation, bleeding, or infection.

Progression-free and overall survival:

Mean progression-free survival for all patients was 17.6 ± 4.7 months, ranging from 8.5 to 21.2 months (Table 3). Progression-free survival was longer for the three patients with resected tumors compared to the three who did not undergo resection (18.9 ± 2.3 months vs 16.2 ± 6.8 months). Overall mean survival (to death or end of study) was 21.6 ± 6.9 months (12.0 to 31.3 months).

Acute and late duodenal toxicity:

All six patients had one or more grade 1 duodenal AEs, with 100% (6/6) having acute and 66.7% (4/6) having late duodenal AEs. Four patients (66.7%) had grade 2 duodenal AEs. Of these four patients, three had acute and three had late duodenal AEs. Two patients (33.3%) had grade 3 duodenal AEs occurring after three months. No patients had grade 4 or 5 duodenal AEs. (See Supplementary Material for tabular summary.)

Pathology:

Of the three patients that qualified for tumor resection, 100% showed no/minimal signs of mucosal damage. One subject (33%) had complete pathologic response (no cancer cells detected on pathology specimen), and two (66.7%) had near complete response. Pathology is included tabularly in Supplementary Material.

Discussion

High-dose ablative radiation is an important advancement in RT, enabling precise delivery of high-dose radiation to a small tumor volume.[15, 16] SBRT (the approach used in the majority of patients in this study) has shown promise for use in pancreatic cancer,[17, 18] but the tissues

adjacent to the pancreas raise substantial concerns about late gastrointestinal toxicity.[19, 20] The duodenum, a radiosensitive organ, limits RT dosing of the HOP.[15, 21]

This study adds to findings from animal and cadaver studies and a single-site pilot study,[6, 7, 11] all of which showed the feasibility of administering and creating space with PEG hydrogel between the HOP and the duodenum. The current study provides evidence for a lack of AEs that would delay RT.

A leading concern following injection of a spacing agent would be causing acute pancreatitis. In this study, there were no reports of pancreatitis following the index procedure. Another potential concern is injection into the duodenal wall and resulting toxicity. The patients in this study who were resected did not have any significant toxicity to the duodenal wall. In the previous porcine study, the same PEG hydrogel was injected directly into duodenal wall and no necrosis was observed.[11]

Although the multi-site design of this study builds on the previous evidence of feasibility, conclusions about the clinical relevance of PEG hydrogel for use in borderline resectable or locally advanced pancreatic cancer are limited by small sample size and the high morbidity and mortality rate. Poor survival outcomes are typical of a pancreatic cancer population, but none of the SAEs that led to death were attributed to PEG hydrogel or RT. The concept of enhancing RT for pancreatic cancer by using PEG hydrogel to create peri-duodenal space warrants further investigations.

Acknowledgments:

The authors thank Jeya Satheesh of Boston Scientific for project management of the TIPS study, Danielle Vannan of Boston Scientific for assistance with manuscript review, Guanghui Liu of Boston Scientific for biostatistics analysis, and Rich Clabaugh of Boston Scientific for creating the illustration showing hydrogel placement. We thank the investigators, staff, and patients in all study sites: Johns Hopkins University, MD Anderson Cancer Center, and Massachusetts General Hospital.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 2019;69:7-34. doi: <u>https://doi.org/10.3322/caac.21551</u>.

2. American Cancer Society. Cancer Facts & Figures 2020 Atlanta: American Cancer Society; 2020 [cited 2022 Sep 23]. Available from: <u>https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf</u>.

3. Thomas TO, Hasan S, Small W, Jr., Herman JM, Lock M, Kim EY, et al. The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far? J Gastrointest Oncol. 2014;5:236-46. Epub 2014/07/02. doi: 10.3978/j.issn.2078-6891.2014.024. PubMed PMID: 24982772; PubMed Central PMCID: PMCPMC4074956.

4. Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D, et al. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015;92:971-7. Epub 2015/06/10. doi: 10.1016/j.ijrobp.2015.04.030. PubMed PMID: 26054865.

5. Song DY, Herfarth KK, Uhl M, Eble MJ, Pinkawa M, van Triest B, et al. A multiinstitutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes. Int J Radiat Oncol Biol Phys. 2013;87:81-7. Epub 2013/02/19. doi: 10.1016/j.ijrobp.2012.12.019. PubMed PMID: 23414766; PubMed Central PMCID: PMCPMC3737267.

6. Kim SH, Ding K, Rao A, He J, Bhutani MS, Herman JM, et al. EUS-guided hydrogel microparticle injection in a cadaveric model. J Appl Clin Med Phys. 2021;22:83-91. Epub 2021/05/25. doi: 10.1002/acm2.13266. PubMed PMID: 34028956; PubMed Central PMCID: PMCPMC8200447.

7. Rao AD, Shin EJ, Meyer J, Thompson EL, Fu W, Hu C, et al. Evaluation of a Novel Absorbable Radiopaque Hydrogel in Patients Undergoing Image Guided Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. Pract Radiat Oncol. 2020;10:e508-e13. Epub 2020/03/11. doi: 10.1016/j.prro.2020.01.013. PubMed PMID: 32151732; PubMed Central PMCID: PMCPMC7483342.

8. Alexander A, Ajazuddin, Khan J, Saraf S, Saraf S. Polyethylene glycol (PEG)–Poly(Nisopropylacrylamide) (PNIPAAm) based thermosensitive injectable hydrogels for biomedical applications. Eur J Pharm Biopharm. 2014;88:575-85. doi: https://doi.org/10.1016/j.ejpb.2014.07.005.

9. Hatiboglu G, Pinkawa M, Vallée JP, Hadaschik B, Hohenfellner M. Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy. BJU Int. 2012;110:E647-52. Epub 2012/07/14. doi: 10.1111/j.1464-410X.2012.11373.x. PubMed PMID: 22788857.

10. de Souza Lawrence L, Ford E, Gilbert C, Yarmus L, Meneshian A, Feller-Kopman D, et al. Novel Applications of an Injectable Radiopaque Hydrogel Tissue Marker for Management of Thoracic Malignancies. Chest. 2013;143:1635-41. doi: <u>https://doi.org/10.1378/chest.12-1691</u>.

11. Rao AD, Shin EJ, Beck SE, Garrett C, Kim SH, Lee NJ, et al. Demonstration of Safety and Feasibility of Hydrogel Marking of the Pancreas-Duodenum Interface for Image Guided Radiation Therapy (IGRT) in a Porcine Model: Implications in IGRT for Pancreatic Cancer Patients. Int J Radiat Oncol Biol Phys. 2018;101:640-5. Epub 2018/04/24. doi:

10.1016/j.ijrobp.2018.02.024. PubMed PMID: 29680252; PubMed Central PMCID: PMCPMC6064682.

12. Narang AK, Hong TS, Ding K, Herman J, Meyer J, Thompson E, et al. A Multi-Institutional Safety and Feasibility Study Exploring the Use of Hydrogel to Create Spatial Separation between the Pancreas and Duodenum in Patients with Pancreatic Cancer. Practical Radiation Oncology. 2023. doi: <u>https://doi.org/10.1016/j.prro.2023.11.011</u>.

13. Verma V, Lazenby AJ, Zheng D, Bhirud AR, Ly QP, Are C, et al. Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial. Radiother Oncol. 2017;122:464-9. Epub 2017/01/17. doi: 10.1016/j.radonc.2016.12.030. PubMed PMID: 28089484; PubMed Central PMCID: PMCPMC5346338.

14. Burgart LJ, Chopp WV, Jain D. Protocol for the Examination of Specimens from Patients with Carcinoma of the Pancreas, version 4.2.0.0: College of American Pathologists (CAP); 2021 [cited 2024 Feb 2]. Available from:

https://documents.cap.org/protocols/Panc.Exo 4.2.0.0.REL CAPCP.pdf.

15. Crane CH, Willett CG. Stereotactic radiotherapy for pancreatic cancer? Cancer. 2009;115:468-72. Epub 2009/01/02. doi: 10.1002/cncr.24069. PubMed PMID: 19117338.

16. Goldsmith C, Plowman PN, Green MM, Dale RG, Price PM. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity. Radiat Oncol. 2018;13:204. Epub 2018/10/21. doi: 10.1186/s13014-018-1138-3. PubMed PMID: 30340643; PubMed Central PMCID: PMCPMC6194644.

17. de Geus SWL, Eskander MF, Kasumova GG, Ng SC, Kent TS, Mancias JD, et al. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Cancer. 2017;123:4158-67. Epub 2017/07/15. doi: 10.1002/cncr.30856. PubMed PMID: 28708929.

18. Tozzi A, Comito T, Alongi F, Navarria P, Iftode C, Mancosu P, et al. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiat Oncol. 2013;8:148. Epub 2013/06/27. doi: 10.1186/1748-717x-8-148. PubMed PMID: 23799996; PubMed Central PMCID: PMCPMC3707803.

19. Ko AH, Crane CH. Radiation therapy in operable and locally advanced pancreatic cancer. J Natl Compr Canc Netw. 2010;8:1022-31. Epub 2010/09/30. doi: 10.6004/jnccn.2010.0074. PubMed PMID: 20876542.

20. Koay EJ, Hanania AN, Hall WA, Taniguchi CM, Rebueno N, Myrehaug S, et al. Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Pract Radiat Oncol. 2020;10:e495-e507. Epub 2020/02/18. doi: 10.1016/j.prro.2020.01.012. PubMed PMID: 32061993; PubMed Central PMCID: PMCPMC7423616.

21. Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009;115:665-72. doi: <u>https://doi.org/10.1002/cncr.24059</u>.

Tables

Table 1. Patient Characteristics

Baselin	e Demographics and Clinical Charac	teristics	
	5.1	Patients (N=6)	
Age (years)	Ν	6	
	Mean ± SD	69.5 ± 7.4	
	Median	69.5	
	Range	60.0 - 80.0	
Sex	Male	4 (66.7%)	
	Female	2 (33.3%)	
Ethnicity	Hispanic or Latino	1 (16.7%)	
-	Not Hispanic or Latino	5 (83.3%)	
Race	White	3 (50.0%)	
	Black/African American	2 (33.3%)	
	Asian	1 (16.7%)	
	American Indian/Alaskan	0 (0.0%)	
	Native		
	Native Hawaiian/Pacific	0 (0.0%)	
	Islander		
Smoking history	Current Smoker	0 (0.0%)	
5 ,	Past Smoker	2 (33.3%)	
	Never Smoked	4 (66.7%)	
BMI	Ν	4	
	Mean ± SD	29.9 ± 5.4	
	Median	32.1	
	Min, Max	22.0 - 33.5	
	Pancreatic Cancer Medical History		
Neoadjuvant therapy for	No	0 (0.0%)	
pancreatic cancer	Yes	6 (100.0%)	
Largest pre-treatment dimension	Ν	6	
of tumor (cm)	Mean (SD)	3.0 ± 0.6	
	Median	3.2	
	Min, Max	2.2 - 3.5	
Initial resect status Borderline Resectable		4 (66.7%)	
	Locally Advanced	2 (33.3%)	
Initial tumor anatomic stage	Stage 0	0 (0.0%)	
Stage IA		0 (0.0%)	
	Stage IB	3 (50.0%)	
	Stage IIA	1 (16.7%)	

Patient	22 Gauge Dilution Ratio	Number of Injections	Total Volume	Pre- injection Space (mm)	Post-Injection Space 1 (mm)	Post-Injection Space 2 (mm)	Post-Injection Space 3 (mm)
1	1:1	3	3mL	1	6.84	3.96	8.95
2	3:1	3	2.5 mL	1	5.56	7.89	5.73
3	3:1	4	3.75 mL	1	10.78	7.99	6.76
4	3:1	3	3 mL	1	5.85	3.19	3.89
5	No dilution	12	10 mL	1	12.35	10.52	9.16
6	No dilution	6	6 mL	1	10.16	8.78	10.83

Table 3. Progression-Free Survival and Overall Survival

		Total (N=6)	Resected (N=3)	Not Resected (N=3)
Progression-Free Survival (months)	Mean ± SD	17.6 ± 4.7	18.9 ± 2.3	16.2 ± 6.8
(In patients with tumor progression event)	Median	18.9	18.8	19.0
	Min - Max	8.5 - 21.2	16.7 - 21.2	8.5 - 21.1
Overall Survival (months)	Mean ± SD	21.6 ± 6.9	20.0 ± 3.4	23.3 ± 10.0
	Median	21.7	20.0	26.5
	Min - Max	12.0 - 31.3	16.7 - 23.4	12.0 - 31.3

Table and Figure Legends

Table 1. Patient Characteristics

Table 2. Injection Characteristics by Patient

Table 3. Progression-Free Survival and Overall Survival

Figure 1. PEG Hydrogel

Figure 1a. Injectable PEG hydrogel used in the study

Figure 1b. PEG hydrogel injection (blue) into the peri-duodenal space (black dotted line) between the duodenum and pancreas tumor using endoscopic ultrasound guidance

Figure 2. Injection and post-injection EUS images

Figure 2a. Transduodenal PEG hydrogel injection with a 22 G EUS FNA needle (needle tip circled in red) with a hypoechoic nodule (margins indicated by arrows) developing around the needle tip after the injection

Figure 2b. Injection of PEG hydrogel with 22 G EUS FNA needle between the duodenum and the pancreatic head mass with a hypoechoic nodule forming around the tip of the needle

Figure 2c. After injection of PEG hydrogel in the same patient as in 2b, there is a hypoechoic nodule (arrow) separating the pancreatic head tumor from the duodenal wall by 7.6mm

Figure 3. PEG hydrogel between the duodenum and pancreatic head tumor on CT scan

Figure 3a: Contrast enhanced CT scan showing pancreatic head tumor and metal biliary stent prior to PEG hydrogel injection.

Figure 3b-3d: Contrast enhanced CT scan post-injection showing the PEG hydrogel (in blue outline) clearly visible and separating the duodenal wall from the pancreatic head for stereotactic radiation therapy (axial, coronal, and sagittal planes in same patient as shown in 3a).







Accepted Manuscript